• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Hancock Jaffe touts early results of VenoValve study

Hancock Jaffe touts early results of VenoValve study

July 29, 2019 By Nancy Crotti

Hancock Jaffe Labs

Hancock Jaffe Laboratories (NSDQ:HJLI) said today that reflux has been reduced to normal levels in four of the first patients to receive its VenoValve device, 90 days after implantation.

The VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis, the Irvine, Calif.-based company said. Reflux is the primary end point for HJLI’s ongoing VenoValve trial first-in-human clinical trial in Bogota, Colombia, and is the main cause of severe chronic venous insufficiency (CVI) of the deep vein system.

Principal investigator Dr. Jorge Hernando Ulloa  reported that overall, reflux has been reduced an average of 68% across all patients with the working VenoValve device, compared with the 45% reduction that was reported in June, when patients were 60 days post-surgery. Venous clinical severity scores, which measure venous disease severity graded by the clinician, has also continued to improve, with the average improvement across all four patients now at forty-nine percent (49%), compared to pre-operative levels, the company said. Pain across the patients decreased 39%. Ulloa reported the data at the second annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean.

“Our 90-day data shows substantial improvement in our patients in all important areas. In addition, we have not experienced any significant device related adverse events,” said HJLI CEO Robert Berman in a news release. “At this point, the results that we are seeing with the VenoValves is exceptional.”

HJLI expects to release 180-day results for these patients, and incremental results for other patients enrolled in the study, in October. The company expects to use the data from its first-in-man Bogota study as part of  an investigational device exemption application, to be submitted to the the FDA in early 2020.

Filed Under: Blog, Clinical Trials, Food & Drug Administration (FDA), News Well, Vascular Tagged With: FDA, hancockjaffelabs

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy